MiR-138 acts as a tumor suppressor in many types of cancer and, through its binding at the 3′UTR of CTLA-4 and PD-1, reduces glioma cell growth in vivo by suppressing immune checkpoint expression in human CD4+ T lymphocytes [91]. This evidence concerns the gene CD4 and neoplasm.